STERIS (STE) to Release Earnings on Wednesday

STERIS (NYSE:STE) is expected to announce its Q1 2027 results after the market closes on Wednesday, August 5th. Analysts expect STERIS to post earnings of $2.49 per share and revenue of $1.4949 billion for the quarter. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Interested persons may visit the the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.74 earnings per share. On average, analysts expect STERIS to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

STERIS Stock Performance

STE stock opened at $228.75 on Monday. The stock’s 50 day simple moving average is $212.99 and its 200 day simple moving average is $226.32. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. STERIS has a 12-month low of $195.14 and a 12-month high of $269.44. The stock has a market capitalization of $22.29 billion, a PE ratio of 28.85 and a beta of 0.91.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a $0.69 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Friday, September 4th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Insider Activity

In other news, VP John Adam Zangerle sold 1,419 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the transaction, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director directly owned 38,964 shares of the company’s stock, valued at $8,163,347.64. The trade was a 3.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,328 shares of company stock valued at $1,554,051 in the last ninety days. 1.12% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On STERIS

Large investors have recently made changes to their positions in the company. Elevation Point Wealth Partners LLC bought a new position in shares of STERIS in the 4th quarter worth approximately $223,000. Compound Planning Inc. bought a new stake in STERIS during the fourth quarter valued at approximately $220,000. Hilltop Holdings Inc. bought a new stake in STERIS during the fourth quarter valued at approximately $218,000. Aptus Capital Advisors LLC purchased a new stake in STERIS during the fourth quarter valued at approximately $200,000. Finally, Smartleaf Asset Management LLC increased its holdings in STERIS by 20.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 646 shares of the medical equipment provider’s stock valued at $165,000 after buying an additional 109 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wall Street Zen downgraded STERIS from a “buy” rating to a “hold” rating in a report on Saturday. UBS Group started coverage on STERIS in a report on Tuesday, July 28th. They issued a “buy” rating and a $275.00 price objective for the company. KeyCorp decreased their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Piper Sandler restated an “overweight” rating and set a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Finally, Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $277.25.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.